Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer.[1] He led the development of gemcitabine,[2] and has several drugs in development.
RAC Price at posting:
$1.82 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)